In the future, developing antagonists against IL-17A or IL-17A receptors, manufacturing IL-1β monoclonal antibodies, and conducting NLRP3 inhibitor or caspase-1 inhibitor-related immunotherapy studies aimed at finding a way to block the pathway of IL-17A promoting IL-1β secretion, may help prevent the development of GO. This evidence concerns the gene IL17A and geroderma osteodysplastica.